ArticleScientific reports2026
Intravitreal rezafungin and anidulafungin in a rabbit model of Aspergillus fumigatus endophthalmitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rezafungin (RZF) and anidulafungin (AFG) are echinocandins with potential for treating Aspergillus fumigatus endophthalmitis. We evaluated their antifungal and anti-inflammatory effects in vitro and in a rabbit endophthalmitis model. In vitro, minimum effective concentrations and minimum inhibitory concentrations were determined, biofilm inhibition was assessed, and drug-induced structural damage was examined by confocal laser scanning microscopy, scanning electron microscopy and transmission electron microscopy. TNF-α and IL-1β mRNA levels in RAW 264.7 macrophages were measured to assess inflammatory regulation. In vivo, a rabbit model of A. fumigatus endophthalmitis was established and, 24 h after infection, eyes received a single intravitreal injection of liposomal amphotericin B, voriconazole, RZF, AFG or normal saline. Clinical inflammation scores, intraocular fungal burden, aqueous humor TNF-α levels and histopathological changes were compared among groups. RZF and AFG showed low minimum effective concentrations, inhibited biofilm formation, disrupted fungal cell wall and membrane integrity in vitro and significantly reduced intraocular inflammation, fungal burden and aqueous humor TNF-α in vivo, with overall efficacy comparable to that of liposomal amphotericin B and voriconazole. These findings support RZF and AFG as promising alternative agents for intravitreal therapy of A. fumigatus endophthalmitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.